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ABSTRACT 
Background: Infections after epidural and spinal blocks are rare. The topi- 
cal anesthetic liclocaine used in these procedures has been found to have anti- 
bacterial effects on various microorganisms. 
Objective: The aim of this study was to assess the antibacterial effects of 
alkalinized liclocaine on Staphylococcus aureus, Escherichia coli, and Pseudomonas 
aeruginosa. 
Methods: Lidocaine 2%, alkalinized lidocaine, and physiologic saline (as a 
control solution) were added to standard bacterial preparations. The final con- 
centration of the lidocaine was 10 mg/mL (1%). At baseline and 3 and 6 hours 
after incubation at 37°C, 3-mL aliquots were vortexed and pipetted into sterile 
polystyrene spectrophotometer cuvettes. Baseline referred to the end of the 
period of preparation of the solution (_<20 minutes). Growth was measured as 
the optical density at a wavelength of 540 nm. 
Results: Compared with the control, lidocaine significantly inhibited the 
growth of S aureus, E coli, and P aeruginosa t baseline and 3 and 6 hours after 
incubation (all, P < 0.05). Alkalinized lidocaine significantly inhibited the growth 
of S aureus at baseline and 3 and 6 hours (all, P < 0.05), while it significantly 
inhibited the growth of E coli and P aeruginosa only at 6 hours (both, P < 0.05). 
The growth of E coli was significantly less in lidocaine than in alkalinized lido- 
caine at 0 and 3 hours (both, P < 0.05). 
Conclusion: The antibacterial effect of lidocaine 1% on S aureus was not 
changed after alkalinization. The effect of alkalinized lidocaine on E coli and 
P aeruginosa was significant only at 6 hours. Lidocaine significantly inhibited 
the growth of these 3 microorganisms at all study periods. (Curr Ther Res Clin 
Exp. 2007;68:242-248) Copyright © 2007 Excerpta Medica, Inc. 
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INTRODUCTION 
Various studies have found that bupivacaine, ropivacaine, lidocaine, and levo- 
bupivacaine inhibit the growth of bacteria in vitro. 1-3 Lidocaine is thought o 
inhibit bacterial growth through its effects on either the cell wall or cytoplas- 
mic membrane. 4 It has been shown to inhibit the incorporation of radioactive 
precursors of DNA, RNA, and proteins; however, the drug has not been shown 
to inhibit macromolecular synthesis. 5 It has been suggested that lidocaine dis- 
rupts bacterial membrane potential through depolarization of the cytoplasmic 
membrane. 4 Infections after epidural and spinal blocks are rare, which might be 
related to the antibacterial effect of local anesthetics such as lidocaine. 6,7 
The pH of local anesthetics i increased by coadministration of sodium 
bicarbonate. Using this method, the nonionized portion of a local anesthetic 
may be increased, resulting in the onset of anesthesia t a lower serum-drug 
concentration, greater spread of the drug, and a longer duration of anesthe- 
sia; in short, improvement in the quality of anesthesia. 8-1° However, studies of 
the antibacterial effect of alkalinized lidocaine using sodium bicarbonate are 
limited. 11,12 Studies have reported conflicting findings of the antibacterial ef- 
fectiveness of sodium bicarbonate at different doses: sodium bicarbonate 
100 mEq/L was found to be effective, 11while sodium bicarbonate 100 mEq/mL 
was not effective. 12 
The normal flora of human epidermis includes Staphylococcus aureus, 
Escherichia coli, and Pseudomonas aeruginosa, all of which are responsible for 
nosocomial infections and are also frequently isolated from spinal and epidural 
abscesses. 2,13,14 Therefore, the aim of this study was to assess the antibacterial 
effects of alkalinized lidocaine on these 3 microorganisms in vitro. 
MATERIALS AND METHODS 
All tests were performed in an accredited laboratory by experienced scientists 
using approved materials. Review of the study by an institutional review board 
(IRB) was waived because this was an in vitro study. However, the researchers 
were aware of the Inonu University IRB's policies and procedures as they 
related to this study. Copies of the IRB's written procedures were distributed to 
all individuals involved in the study who had research responsibilities. 
Solutions of lidocaine 2% and alkalinized lidocaine* were used in this study. Lido- 
caine was alkalinized with sodium bicarbonate (1 mL 8.4% sodium bicarbonate/ 
10 mL lidocaine 2%). Sample pH was measured using a PHM 84 Research pH meter 
(Radiometer, Copenhagen, Denmark) calibrated to a pH of 7.000 with a certified 
standard buffer (Fisher Scientific, Fair Lawn, New Jersey). The pH of lidocaine 
was 6.3 before alkalinization and 7.2 after alkalinization. 
S aureus, E coli, and P aeruginosa (American Type Culture Collection [ATCC] 
numbers 25923, 25922, and 27853, respectively [ATCC, Manassas, Virginia]) were 
*Trademark: Aritmal ® 2% (Biosel, Istanbul, Turkey). 
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grown on standard blood agar and incubated at 37°C for 24 hours. Fresh bac- 
terial cultures were prepared to match the turbidity of a McFarland 0.5 scale 
(108 colony-forming units [CFUs]/mL) with sterile saline 0.9%, and each solu- 
tion was further diluted in Mueller-Hinton broth to obtain standard inocula 
(105 CFU/mL). 
The test solutions and the control solution (physiologic saline) were added to 
2 mL of standard bacterial preparations. The final concentration of lidocaine was 
10 mg/mL (1%). 
At baseline and at 3 and 6 hours after incubation at 37°C, 3-mL aliquots were 
vortexed and pipetted into sterile polystyrene spectrophotometer cuvettes. Bac- 
terial growth was measured as the absorption of light at a wavelength of 540 nm 
(absorption A540) (Ultrospec Plus, Pharmacia LKB Biochrom Ltd., Cambridge, 
United Kingdom). Baseline refers to the end of the period used to prepare the solu- 
tion (<20 minutes). 
Each experiment was repeated 5 times and each test was performed induplicate. 
Statistical Analysis 
The results are expressed as mean (SD). All results were shown to be abnor- 
mally distributed according to the Shapiro-Wilks test. Differences between 
groups were evaluated using the Mann-Whitney test. The Wilcoxon signed rank 
test was used for intragroup comparisons. P < 0.05 was considered to be sta- 
tistically significant. All statistical analyses were performed using SPSS for 
Windows, version 10.0 (SPSS Inc., Chicago, Illinois). 
RESULTS 
Compared with the control solution, lidocaine significantly inhibited the growth 
of S aureus at baseline and after 3 and 6 hours of incubation (mean [SD] absorp- 
tion, 0.01 [0.01]; P = 0.001, P < 0.001, and P = 0.004, respectively). Alkalinized 
lidocaine significantly inhibited the growth of S aureus at baseline and 3 hours 
(both, 0.02 [0.01]; P = 0.005 and P = 0.002, respectively) and at 6 hours (0.01 
[0.01]; P< 0.001) (Figure 1). 
Compared with the control solution, lidocaine significantly inhibited the 
growth of E coli at baseline and after 3 and 6 hours of incubation (all, 0.02 [0.01]; 
P = 0.006, P = 0.001, and P < 0.001, respectively). Alkalinized lidocaine signifi- 
cantly inhibited the growth of E coli only at 6 hours (0.04 [0.04]; P < 0.001). 
Compared with alkalinized lidocaine, lidocaine significantly inhibited the 
growth of Ecol i  at baseline and 3 hours (both, 0.02 [0.01]; P= 0.036 andP= 0.015, 
respectively) (Figure 2). 
Compared with the control solution, lidocaine significantly inhibited the 
growth of Paeruginosa t baseline and 3 and 6 hours after incubation (0.01 [0.01], 
0.01 [0.00], and 0.02 [0.02]; P = 0.004, P < 0.001, and P = 0.002, respectively). 
Alkalinized lidocaine significantly inhibited the growth of P aeruginosa t 6 hours 
(0.02 [0.01]; P< 0.001) (Figure 3). 
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Figure 1. The (mean [SD]) effect of l idocaine 1% and alkal in ized l idocaine on Staphylo- 
coccus aureus. Lower  absorpt ion  of l ight  at 540 nm indicates greater  inhib i -  
t ion  of g rowth .  *P < 0.05 versus contro l .  
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Figure 2. The (mean [SD]) effect of l idocaine 1% and alkal in ized l idocaine on Esche- 
richia coli. Lower  absorpt ion  of l ight  at 540 nm indicates greater  inh ib i t ion  
of g rowth .  *P < 0.05 versus contro l ;  tp < 0.05 versus a lkal in ized l idocaine. 
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Figure 3. The (mean [SD]) effect of l idocaine 1% and alkal inized l idocaine on Pseudo- 
monas aeruginosa. Lower absorpt ion of l ight  at 540 nm indicates greater  
inh ib i t ion  of g rowth .  *P < 0.05 versus control .  
DISCUSSION 
Both l idocaine and alkal inized l idocaine s ignif icant ly inhibi ted the growth 
of S aureus at all s tudy  points  (basel ine and after 3 and 6 hours  of incuba- 
tion; all, P< 0.05). L idocaine also s ignif icant ly inhibi ted the growth of E coli 
and P aeruginosa at all s tudy  points,  but  alkal inized l idocaine inhibi ted the 
growth of these  bacter ia  only at 6 hours  (P < 0.05). The absorpt ion  of lido- 
caine, alkal inized l idocaine, and the contro l  so lut ion differed at the s tar t  of 
the s tudy  because  adding sod ium b icarbonate  to l idocaine s igni f icant ly 
enhances  absorpt ion .  It has been s tated  that  condi t ions  of temperature ,  
pH, and ionic s t rength  of med ium affect the precip i t in  react ion while the 
contro l  so lut ion inc luded only bacter ia ,  broth,  and phys io log ic  sal ine. 15 
Lidocaine is used clinically at var ious concentrat ions  (0.5%-5.0%). 2-5 
Schmidt  and Rosenkranz 5 found that  concentrat ions  as low as l idocaine 0.5% 
reduced the number  of viable bacter ia  in a solut ion of E coi l  They also found 
that  the MIC of l idocaine to S aureus was between 1% and 2%. Aydm et al 2 
found that  l idocaine 5% and 2% reduced the number  of CFUs of S aureus (P = 
0.007 and P = 0.006, respect ively) ,  E coli (P = 0.04 and P = 0.01), P aeruginosa 
(P = 0.009 and P = 0.003), and Candida albicans (P = 0.001 and P = 0.019), while 
l idocaine 1% reduced only the number  of CFUs of P aeruginosa (P = 0.009). We 
found that  l idocaine 1% inhibited S aureus, E coli, and P aeruginosa. The differ- 
ences between our findings and those of other studies may be attr ibutable to 
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the differences in the experimental conditions, including the bacterial strains 
used, the methods of evaluating bacterial growth, and drug dilutions. The 
absorption method used to assess bacterial growth has enhanced sensitivity, 
measuring subnanograms per milliliter of bacteria. 15 The samples used in this 
study had specific turbidity levels, and the levels changed when bacterial 
growth occurred. Growth was measured as the absorption of light at a wave- 
length of 540 nm, with lower absorption indicating reater inhibition of growth. 
Few data are available on the antibacterial ctivity of local anesthetics mixed 
with sodium bicarbonate. In their investigation ofthe antibacterial effectiveness of 
lidocaine, sodium bicarbonate, and epinephrine individually against 2 types of bac- 
teria and 7 fungi often encountered in immunosuppressed patients, Williams et a112 
reported that the use of sodium bicarbonate and epinephrine should be avoid- 
ed when taking biopsy specimens for culture. Their study differed from ours in that 
they used sodium bicarbonate in 12.5-, 25-, and 100-mEq/mL concentrations, while 
we used sodium bicarbonate 100 mEq/L in combination with lidocaine. 
Thompson et a111 reported that sodium bicarbonate combined with lido- 
caine had greater antibacterial effectiveness than lidocaine monotherapy. The 
study was performed with the solution of 4% lidocaine containing 0.1% methyl- 
paraben and epinephrine using 3 concentrations of sodium bicarbonate (25, 50, 
and 100 mEq/L), 6 microorganisms, and the colony counting method. A low 
concentration of lidocaine (1%) was used in our study, while methylparaben a d 
epinephrine were not used. The alkalinization rate was constant (100 mEq/L), 
only 3 microorganisms were used, and the absorption method was used to 
assess bacterial growth. All of these differences in methodology may have 
resulted in the differences in the findings between our study and that of 
Thompson et al. Methylparaben, a preservative often found in lidocaine, has 
also been reported to have antibacterial effects. 16 Further studies of the anti- 
bacterial effects of alkalinized lidocaine using different drug dilutions and dif- 
ferent microorganisms are needed. 
We hold the opinion that because the alkalinized lidocaine did not inhibit 
growth of bacteria studied at baseline and 3 hours after incubation, it should 
be preferred only under certain circumstances. 
CONCLUSION 
The antibacterial effect of lidocaine 1% on S aureus was not changed after alka- 
linization. The effect of alkalinized lidocaine on E coli and P aeruginosa was 
significant only at 6 hours. Lidocaine significantly inhibited the growth of these 
3 microorganisms at all study periods. 
REFERENCES 
1. Batai I, Kerenyi M, Falvai J, Szabo G. Bacterial growth in ropivacaine hydrochloride. 
Anesth Analg. 2002;94:729-731. 
2. Aydin ON, Eyigor M, Aydin N. Antimicrobial activity of ropivacaine and other local 
anaesthetics. EurJAnaesthesiol. 2001;18:687-694. 
247 
CURRENT THERAPEUTIC RESEARCH 
3. Pete P, Lindgren L, Vaara M. Poor antibacterial effect of ropivacaine: Comparison 
with bupivacaine. Anesthesiology. 1999;91:884--886. 
4. Ohsuka S, Ohta M, Masuda K, et al. Lidocaine hydrochloride and acetylsalicylate kill
bacteria by disrupting the bacterial membrane potential in different ways. Microbiol 
Immunol. 1994;38:429--434. 
5. Schmidt RM, Rosenkranz HS. Antimicrobial activity of topical anesthetics: Lidocaine 
and procaine. Jlnfect Dis. 1970;121:597-607. 
6. Hlavin ML, Kaminski H J, Ross JS, Ganz E. Spinal epidural abscess: A ten-year perspec- 
tive. Neurosurgery. 1990;27:177-184. 
7. Sakuragi T, Ishino H, Dan K. Bactericidal activity of clinically used local anesthetics 
on Staphylococcus aureus. Reg Anesth. 1996;21:239-242. 
8. Moore DC. The pH of local anesthetic solutions. Anesth Analg. 1981;60:833-834. 
9. Ramos G, Pereira E, Simonetti MP. Does alkalinization of 0.75% ropivacaine promote 
a lumbar peridural block of higher quality? Reg Anesth Pain Med. 2001;26:357-362. 
10. Curatolo M, Petersen-Felix S,Arendt-Nielsen L, et al. Adding sodium bicarbonate to 
lidocaine nhances the depth of epidural blockade. Anesth Analg. 1998;86:341-347. 
11. Thompson KD, Welykyj S, Massa MC. Antibacterial activity of lidocaine in combina- 
tion with a bicarbonate buffer. JDermatol Surg Oncol. 1993;19:216-220. 
12. Williams B J, Hanke CW, Bartlett M. Antimicrobial effects of lidocaine, bicarbonate, 
and epinephrine. JAm AcadDermatol. 1997;37:662-664. 
13. Sakuragi T, Ishino H, Dan K. Bactericidal activity of preservative-free bupivacaine on 
microorganisms in the human skin flora. Acta Anaesthesiol Scand. 1998;42:1096-1099. 
14. Goodman EJ, Jacobs MR, Bajaksouzian S, et al. Clinically significant concentrations 
of local anesthetics inhibit Staphylococcus aureus in vitro. Int J Obstet Anesth. 
2002;11:95-99. 
15. Henry JB. Immunoassays and immunochemistry. In: Kasahara Y, Nakamura RM. 
Clinical Diagnosis and Management by Laboratory Methods. 19th ed. Philadelphia, Pa: 
W.B. Saunders Company; 1996:851-876. 
16. Miller MA, Shelley WB. Antibacterial properties of lidocaine on bacteria isolated 
from dermal esions. Arch Dermatol. 1985;121:1157-1159. 
Address correspondence to: Zekine Begec, MD, T. Ozal Tip Merkezi 
Anesteziyoloj i  ve Reanimasyon AD, 44315 Malatya, Turkey. E-mail: zozpolat@ 
inonu.edu.tr  
248 
